Overexpression of CXCR4 in mesenchymal stem cells promotes migration, neuroprotection and angiogenesis in a rat model of stroke

Yu, Xiaolan; Chen, Dongping; Zhang, Yang; Wu, Xiuli; Huang, Zhi-Xing; Zhou, Haitao; Zhang, Yanding; Zhang, Zhijian

doi:10.1016/j.jns.2012.01.001

Cited by 91 publications

(74 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CXCR4, an upstream molecule of the PI3 kinase/Akt pathway, has been shown to play critical roles in several aspects of tumor progression, such as angiogenesis, metastasis, and survival 33, 34, 35, 36, 37. An earlier study suggested that CD164 acted as a component of a CXCR4 complex and regulated the migration of CD133 + cells.…”

Section: Discussionmentioning

confidence: 99%

CD164 promotes tumor progression and predicts the poor prognosis of bladder cancer

Zhang

Li³

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

CD164 was found to play a role in many malignant diseases. But the roles of CD164 in human bladder cancer have not yet been studied. The object of our study was to investigate the functions of CD164 in urothelial bladder carcinoma. The immunohistochemistry (IHC) was performed to evaluate the associations between the expression level of CD164 and clinical‐pathological features of patients, and IHC was used to analyze the relationship between CD164 and CXCR4 in tumor tissues. Real‐time qPCR and Western blot were used to measure the expression of relevant genes. The roles of CD164 in tumor cells and tissues were investigated by in vitro and in vivo experiments. The results of immunohistochemistry found that CD164 was associated with clinical and pathological features of patients. High level of CD164 was related to the distant metastasis and vascular invasion of bladder cancer patients. In vitro, by silencing of CD164, the proliferation, migration, and invasion of tumor cells were inhibited significantly by regulating related proteins such as Ki67, proliferating cell nuclear antigen, matrix metalloproteinases‐2, and matrix metalloproteinases‐9. In vivo, knocking‐down of CD164 could reduce the growth and metastasis of tumors in mice. In addition, a co‐expression was found between CD164 and CXCR4 in tumor tissues. In conclusion, our study demonstrated that CD164 was associated with the poor clinical outcomes of BC patients. Silencing of CD164 could inhibit the progression of tumors in vivo and in vitro, which may become an effective target in the treatment of bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

CD164 promotes tumor progression and predicts the poor prognosis of bladder cancer

Zhang

Li³

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…CXCR4-rMSCs 24 h CXCR4 overexpression in BMSCs promoted mobilization [58] and migration, enhanced neuroprotection.…”

Section: Permanent Mcao IV Noggin-bmscs 5 Daysmentioning

confidence: 96%

“…The interaction between SDF-1α and its cognate receptor CXCR4 is crucial for the homing and migration of multiple stem-cell types [58,65] . In the early phase of recovery from ischemic stroke, CXCR4 expressed by BMSCs can be activated [66] .…”

Section: Permanent Mcao IV Noggin-bmscs 5 Daysmentioning

confidence: 99%

See 1 more Smart Citation

Bone marrow stromal cells as a therapeutic treatment for ischemic stroke

Yang

Zhu

et al. 2014

Neurosci. Bull.

View full text Add to dashboard Cite

Cerebral ischemia remains the most frequent cause of death and quality-of-life impairments due to neurological deficits, and accounts for the majority of total healthcare costs. However, treatments for cerebral ischemia are limited. Over the last decade, bone marrow stromal cell (BMSC) therapy has emerged as a particularly appealing option, as it is possible to help patients even when initiated days or even weeks after the ischemic insult. BMSCs are a class of multipotent, self-renewing cells that give rise to differentiated progeny when implanted into appropriate tissues. Therapeutic effects of BMSC treatment for ischemic stroke, including sensory and motor recovery, have been reported in pre-clinical studies and clinical trials. In this article, we review the recent progress in BMSC-based therapy for ischemic stroke, focusing on the route of delivery and pre-processing of BMSCs. Selecting an optimal delivery route is of particular importance. The ideal approach, as well as the least risky, for translational applications still requires further identification. Appropriate preprocessing of BMSCs or combination therapy has the benefi t of achieving the maximum possible restoration. Further pre-clinical studies are required to determine the time-window for transplantation and the appropriate dosage of cells.

show abstract

“…Only a small proportion of BMSCs expresses functionally active CXCR4 receptor on their surface and this expression diminished with passage, but CXCR4 is key to mediating specific migration of these cells (23,24). Overexpression of CXCR4 by genetic modification enhances the ability of MSCs to respond to SDF-1-induced chemotaxis in vitro and promotes MSC recruitment around the ischemic core in vivo (25).…”

Section: μM) (E)mentioning

confidence: 99%

Transplantation of bone marrow mesenchymal stem cells pretreated with valproic acid in rats with an acute spinal cord injury

Chen

Cui

et al. 2014

BST

View full text Add to dashboard Cite

Overexpression of CXCR4 in mesenchymal stem cells promotes migration, neuroprotection and angiogenesis in a rat model of stroke

Cited by 91 publications

References 45 publications

CD164 promotes tumor progression and predicts the poor prognosis of bladder cancer

CD164 promotes tumor progression and predicts the poor prognosis of bladder cancer

Bone marrow stromal cells as a therapeutic treatment for ischemic stroke

Transplantation of bone marrow mesenchymal stem cells pretreated with valproic acid in rats with an acute spinal cord injury

Contact Info

Product

Resources

About